Published in Cell Signal on November 01, 2002
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
The mammalian ovary from genesis to revelation. Endocr Rev (2009) 2.31
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev (2013) 1.60
Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov (2009) 1.60
Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br J Pharmacol (2004) 1.48
Premature ovarian aging in mice deficient for Gpr3. Proc Natl Acad Sci U S A (2005) 1.41
The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat Rev Neurosci (2011) 1.30
Regulation of meiotic prophase arrest in mouse oocytes by GPR3, a constitutive activator of the Gs G protein. J Cell Biol (2005) 1.24
Oocyte-specific expression of Gpr3 is required for the maintenance of meiotic arrest in mouse oocytes. Dev Biol (2005) 1.22
Cell type-specific transcriptomics of hypothalamic energy-sensing neuron responses to weight-loss. Elife (2015) 1.05
The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther (2009) 0.95
A G(s)-linked receptor maintains meiotic arrest in mouse oocytes, but luteinizing hormone does not cause meiotic resumption by terminating receptor-G(s) signaling. Dev Biol (2007) 0.93
Current Screens Based on the AlphaScreen Technology for Deciphering Cell Signalling Pathways. Curr Genomics (2009) 0.91
Deletion of the novel oocyte-enriched gene, Gpr149, leads to increased fertility in mice. Endocrinology (2009) 0.86
GPR3 receptor, a novel actor in the emotional-like responses. PLoS One (2009) 0.86
The Gs-linked receptor GPR3 inhibits the proliferation of cerebellar granule cells during postnatal development. PLoS One (2009) 0.86
Constitutive Activity among Orphan Class-A G Protein Coupled Receptors. PLoS One (2015) 0.84
A role for GPRx, a novel GPR3/6/12-related G-protein coupled receptor, in the maintenance of meiotic arrest in Xenopus laevis oocytes. Dev Biol (2008) 0.83
Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. PLoS One (2011) 0.83
Hunting for the function of orphan GPCRs - beyond the search for the endogenous ligand. Br J Pharmacol (2014) 0.82
The orphan receptor GPR3 modulates the early phases of cocaine reinforcement. Br J Pharmacol (2012) 0.81
The G protein coupled receptor 3 is involved in cAMP and cGMP signaling and maintenance of meiotic arrest in porcine oocytes. PLoS One (2012) 0.81
New insights into ovarian function. Handb Exp Pharmacol (2010) 0.81
Discrete influx events refill depleted Ca2+ stores in a chick retinal neuron. J Physiol (2007) 0.80
G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs. Front Aging Neurosci (2016) 0.78
Sphingosine 1-phosphate acts as an activator for the porcine Gpr3 of constitutively active G protein-coupled receptors. J Zhejiang Univ Sci B (2012) 0.77
Novel Therapeutic GPCRs for Psychiatric Disorders. Int J Mol Sci (2015) 0.77
Intercellular Lipid Mediators and GPCR Drug Discovery. Biomol Ther (Seoul) (2013) 0.77
Vertebrate Reproduction. Cold Spring Harb Perspect Biol (2015) 0.76
Methods to detect cell surface expression and constitutive activity of GPR6. Methods Enzymol (2010) 0.75
Metabolic parameters and emotionality are little affected in G-protein coupled receptor 12 (Gpr12) mutant mice. PLoS One (2012) 0.75
Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer. Oncogene (2015) 0.75
Neuro-psychopharmacological perspective of Orphan receptors of Rhodopsin (class A) family of G protein-coupled receptors. Psychopharmacology (Berl) (2017) 0.75
A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A (2005) 2.31
Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol (2010) 2.11
Heterotrimeric G-proteins: a short history. Br J Pharmacol (2006) 1.79
Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. Sci Signal (2013) 1.71
Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation. Curr Top Med Chem (2006) 1.70
Evidence against a beneficial effect of irisin in humans. PLoS One (2013) 1.68
Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol (2005) 1.54
GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol (2010) 1.39
Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc (2011) 1.26
Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem (2008) 1.25
GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res (2011) 1.21
Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J (2008) 1.17
Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res (2007) 1.15
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.14
Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J Med Chem (2005) 1.12
Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem (2011) 1.09
Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol (2010) 1.07
A physicogenetic method to assign ligand-binding relationships between 7TM receptors. Bioorg Med Chem Lett (2005) 1.06
The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J Biol Chem (2006) 1.06
Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. J Med Chem (2012) 1.06
The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat Commun (2012) 1.05
Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. J Med Chem (2011) 1.03
The C-terminal tail of CRTH2 is a key molecular determinant that constrains Galphai and downstream signaling cascade activation. J Biol Chem (2008) 1.01
Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol (2011) 0.99
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J Med Chem (2009) 0.98
The role of the prostaglandin D2 receptor, DP, in eosinophil trafficking. J Immunol (2007) 0.98
Lack of evidence for AT1R/B2R heterodimerization in COS-7, HEK293, and NIH3T3 cells: how common is the AT1R/B2R heterodimer? J Biol Chem (2008) 0.95
A new ligand for the urotensin II receptor. Br J Pharmacol (2002) 0.95
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.95
Identification of a novel site within G protein alpha subunits important for specificity of receptor-G protein interaction. Mol Pharmacol (2004) 0.93
Conjugated linoleic acids mediate insulin release through islet G protein-coupled receptor FFA1/GPR40. J Biol Chem (2011) 0.93
A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer. Nat Chem Biol (2012) 0.92
Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63. Cell Signal (2003) 0.92
Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin Ther Pat (2010) 0.88
Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J (2012) 0.88
Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes (2013) 0.87
An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators. J Recept Signal Transduct Res (2009) 0.87
Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. ACS Med Chem Lett (2013) 0.87
Regulated and constitutive activation of specific signalling pathways by the human S1P5 receptor. Br J Pharmacol (2003) 0.85
Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. J Pharmacol Exp Ther (2003) 0.84
Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability. J Med Chem (2013) 0.83
Fluid shear stress differentially regulates gpr3, gpr6, and gpr12 expression in human umbilical vein endothelial cells. Cell Physiol Biochem (2003) 0.82
Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol (2003) 0.82
D-type prostanoid receptor enhances the signaling of chemoattractant receptor-homologous molecule expressed on T(H)2 cells. J Allergy Clin Immunol (2011) 0.82
On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2. Mol Pharmacol (2006) 0.82
Muscarinic allosteric modulators: atypical structure-activity-relationships in bispyridinium-type compounds. Arch Pharm (Weinheim) (2006) 0.80
Comparative analysis of functional assays for characterization of agonist ligands at G protein-coupled receptors. J Biomol Screen (2003) 0.80
Comparative analysis of human and rat S1P(5) (edg8): differential expression profiles and sensitivities to antagonists. Biochem Pharmacol (2002) 0.79
A biased non-Gαi OXE-R antagonist demonstrates that Gαi protein subunit is not directly involved in neutrophil, eosinophil, and monocyte activation by 5-oxo-ETE. J Immunol (2014) 0.79
Functional human 5-HT6 receptor assay for high throughput screening of chemical ligands and binding proteins. Comb Chem High Throughput Screen (2008) 0.79
Mining the potential of label-free biosensors for seven-transmembrane receptor drug discovery. Prog Mol Biol Transl Sci (2013) 0.78
PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2. PLoS One (2012) 0.78
Modulation of myocardial contractility by lysophosphatidic acid (LPA). J Mol Cell Cardiol (2003) 0.78
Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity. J Med Chem (2014) 0.77
Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem (2006) 0.77
Label-free biosensor assays in GPCR screening. Methods Mol Biol (2015) 0.76
Mice Lacking Free Fatty Acid Receptor 1 (GPR40/FFAR1) are Protected Against Conjugated Linoleic Acid-Induced Fatty Liver but Develop Inflammation and Insulin Resistance in the Brain. Cell Physiol Biochem (2015) 0.76
Signaling pathways: Purinosomes under GPCR control. Nat Chem Biol (2011) 0.76
Novel insights into appropriate encapsulation methods for bioactive compounds into polymers: a study with peptides and HDAC inhibitors. Macromol Biosci (2013) 0.75
Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1. Bioorg Med Chem Lett (2009) 0.75
Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2. Bioorg Med Chem Lett (2009) 0.75
Detection of free fatty acid receptor 1 expression: the critical role of negative and positive controls. Diabetologia (2014) 0.75
Synthesis and in vitro evaluation of a selective antagonist and the corresponding radioligand for the prostaglandin D2 receptor CRTH2. Bioorg Med Chem Lett (2007) 0.75